SEARCH:   Advanced

Blood, 15 April 2008, Vol. 111, No. 8, pp. 3941-3967. Prepublished online as a Blood First Edition Paper on January 15, 2008; DOI 10.1182/blood-2007-11-120535. This Article Full Text (PDF) All Versions of this Article: blood-2007-11-120535v1 111/8/3941    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Craig, F. E. Articles by Foon, K. A. Search for Related Content PubMed PubMed Citation Articles by Craig, F. E. Articles by Foon, K. A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 2, 2007 Accepted December 20, 2007 Flow cytometric immunophenotyping for hematologic neoplasms Fiona E. Craig* and Kenneth A. Foon Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States * Corresponding author; email: craigfe{at}upmc.edu. Flow cytometric immunophenotyping remains an indispensable tool for the diagnosis, classification, staging, and monitoring of hematologic neoplasms. The last 10 years have seen advances in flow cytometry instrumentation and availability of an expanded range of antibodies and fluorochromes that have improved our ability to identify different normal cell populations and recognize phenotypic aberrancies, even when present in a small proportion of the cells analyzed. Phenotypically abnormal populations have been documented in many hematologic neoplasms including lymphoma, chronic lymphoid leukemias, plasma cell neoplasms, acute leukemia, paroxysmal nocturnal hemoglobinuria, mast cell disease, myelodysplastic syndromes, and myeloproliferative disorders. The past decade has also seen refinement of the criteria used to identify distinct disease entities with widespread adoption of the 2001 WHO classification1. This classification endorses a multiparametric approach to diagnosis and outlines the morphologic, immunophenotypic and genotypic features characteristic of each disease entity. When should flow cytometric immunophenotyping be applied? The recent Bethesda International Consensus Conference on flow cytometric immunophenotypic analysis of hematolymphoid neoplasms made recommendations on the medical indications for flow cytometric testing2. This review discusses how flow cytometric testing is currently applied in these clinical situations and how the information obtained can be used to direct other testing. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. S Grove, G. A Follows, and W. N Erber Incidental finding of lymphocytosis in an asymptomatic patient BMJ, June 10, 2009; 338(jun10_1): b2119 - b2119. [Full Text] A. K. Ho, S. Hill, S. N. Preobrazhensky, M. E. Miller, Z. Chen, and D. W. Bahler Small B-Cell Neoplasms With Typical Mantle Cell Lymphoma Immunophenotypes Often Include Chronic Lymphocytic Leukemias Am J Clin Pathol, January 1, 2009; 131(1): 27 - 32. [Abstract] [Full Text] [PDF] C. Boonthimat, W. Thongnoppakhun, and C. U. Auewarakul Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations Haematologica, October 1, 2008; 93(10): 1565 - 1569. [Abstract] [Full Text] [PDF] T. W. LeBien and T. F. Tedder B lymphocytes: how they develop and function Blood, September 1, 2008; 112(5): 1570 - 1580. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020